0000899243-21-035331.txt : 20210908 0000899243-21-035331.hdr.sgml : 20210908 20210908161519 ACCESSION NUMBER: 0000899243-21-035331 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210907 FILED AS OF DATE: 20210908 DATE AS OF CHANGE: 20210908 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zawel Leigh CENTRAL INDEX KEY: 0001837456 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39856 FILM NUMBER: 211242284 MAIL ADDRESS: STREET 1: C/O CULLINAN MANAGEMENT, INC. STREET 2: ONE MAIN STREET SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cullinan Oncology, Inc. CENTRAL INDEX KEY: 0001789972 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 813867811 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-410-4650 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 520 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Management, Inc. DATE OF NAME CHANGE: 20210107 FORMER COMPANY: FORMER CONFORMED NAME: Cullinan Oncology, LLC DATE OF NAME CHANGE: 20191001 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-09-07 0 0001789972 Cullinan Oncology, Inc. CGEM 0001837456 Zawel Leigh C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 520 CAMBRIDGE MA 02142 0 1 0 0 See Remarks Common Stock 2021-09-07 4 S 0 28118 28.95 D 65406 D Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 26, 2021. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.29. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Chief Scientific Officer, Small Molecules /s/ Jeffrey Trigilio, Attorney-in-Fact 2021-09-08